Policy & Regulation
Lilly's Taltz and Zepbound combination delivers sustained psoriatic arthritis improvements at one year
11 November 2026 - Medicine company Eli Lilly and Company (NYSE: LLY) on Wednesday reported 52-week Phase 3b results showing sustained improvements in disease activity, physical function and metabolic...
Ascletis announces submission of US IND application for oral obesity combination therapy
11 November 2026 - Biotechnology company Ascletis Pharma Inc (HKEX: 1672) reported on Wednesday that it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administrati...
Jubilant Therapeutics to present LSD1 and HDAC6 (CoREST) orally administered dual inhibitor Phase 1/2 study results at 68th ASH Annual Meeting
11 November 2026 - Jubilant Therapeutics Inc, a US-based, clinical-stage biopharmaceutical company that is advancing precision therapeutics for myeloproliferative neoplasms (MPNs), announced on Tuesda...
Abbisko Therapeutics' PIMJETMI receives US FDA approval to treat tenosynovial giant cell tumour (TGCT)
11 November 2026 - Abbisko Therapeutics Co Ltd (HKEX code: 02256.HK), a China-based biopharmaceutical company, announced on Tuesday that the US Food and Drug Administration (FDA) has approved PIMJETMI...
AstraZeneca acquires biotechnology company Omniose to strengthen vaccine capabilities
10 November 2026 - Preclinical biotechnology company Omniose announced on Tuesday that it has been acquired by biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (NYSE:AZN).This acquisition...
Medivir secures US patent protection for fostrox and lenvatinib combination until 2044
10 November 2026 - Swedish pharmaceutical company Medivir AB (STO:MVIR) announced on Tuesday that it has secured a US patent covering the combination of fostroxacitabine bralpamide (fostrox) and lenva...